About MapLight Therapeutics, Inc.
https://www.maplightrx.comMapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
CEO
Christopher A. Kroeger
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public October 24, 2025
Method of going public SPAC
Full time employees 109
ETFs Holding This Stock
Summary
Total 48
Showing Top 3 of 48
Ratings Snapshot
Rating : C+
Discounted Cash Flow 3
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $34
Target Low $28
Target Median $31
Target Consensus $31
Market Cap $13.57 M
52w High $21.55
52w Low $12.24
P/E -7.69
Volume 108.55K
Outstanding Shares 789.34K
About MapLight Therapeutics, Inc.
https://www.maplightrx.comMapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $31.5M ▲ | $-29.42M ▲ | 0% | $-0.71 ▲ | $-31.36M ▼ |
| Q2-2025 | $0 | $30.53M ▲ | $-29.85M ▼ | 0% | $-0.72 ▼ | $-29.71M ▼ |
| Q1-2025 | $0 | $23.38M ▲ | $-22.34M ▼ | 0% | $-0.54 ▼ | $-22.17M ▲ |
| Q4-2024 | $0 | $22.78M ▲ | $-21.23M ▼ | 0% | $-0.51 ▼ | $-22.58M ▼ |
| Q3-2024 | $0 | $20.89M | $-19.02M | 0% | $-0.46 | $-20.71M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $227.17M ▲ | $257.22M ▲ | $531.4M ▲ | $233.52M ▲ |
| Q2-2025 | $60.47M ▼ | $84.12M ▼ | $20.36M ▲ | $63.76M ▼ |
| Q1-2025 | $92.26M ▼ | $111.57M ▼ | $18.57M ▼ | $93M ▼ |
| Q4-2024 | $108.8M ▼ | $136.92M ▼ | $330.54M ▲ | $115.19M ▼ |
| Q1-2024 | $179.81M | $192.57M | $19.75M | $172.83M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-29.42M ▲ | $-31.79M ▲ | $-135.59M ▼ | $198.06M ▲ | $30.68M ▲ | $-31.82M ▲ |
| Q2-2025 | $-29.85M ▼ | $-33.97M ▼ | $17.43M ▼ | $-156K ▼ | $-16.69M ▼ | $-34.03M ▼ |
| Q1-2025 | $-22.34M ▼ | $-25.55M ▼ | $37.5M ▲ | $-47K ▼ | $50.16M ▲ | $-25.55M ▼ |
| Q4-2024 | $-21.23M ▼ | $-21.49M ▼ | $32.39M ▲ | $5K ▲ | $10.91M ▲ | $-21.59M ▼ |
| Q3-2024 | $-19.02M | $-19.85M | $8.64M | $-207K | $-11.42M | $-20.23M |
CEO
Christopher A. Kroeger
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public October 24, 2025
Method of going public SPAC
Full time employees 109
ETFs Holding This Stock
Summary
Total 48
Showing Top 3 of 48
Ratings Snapshot
Rating : C+
Discounted Cash Flow 3
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $34
Target Low $28
Target Median $31
Target Consensus $31